SCHEMBL8049607

SCHEMBL8049607

COc1ccn2ncc(-c3nc4[nH]nc(N5CCCCC5)c4cc3F)c2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 5/20 0.39
MAPK1 P28482 3/20 0.35
TDP1 Q9NUW8 3/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
ALOX15 P16050 2/20 0.35
CASP1 P29466 2/20 0.35
CASP7 P55210 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
TP53 P04637 1/20 0.35
PABPC1 P11940 1/20 0.35
APEX1 P27695 1/20 0.35
RAB9A P51151 1/20 0.35
ATM Q13315 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
DYRK1A Q13627 2/20 0.34
MAPT P10636 2/20 0.33
KCNH2 Q12809 1/20 0.33
RUNX1 Q01196 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8047356 0.92 MAP4K1 (0.38) PDE2AMAPK1MEN1KMT2ADYRK1A
SCHEMBL3243059 0.84 PRMT5 (0.36) PDE2AMEN1KMT2AKDM4EALDH1A1
SCHEMBL13099752 0.84 JAK2 (0.38) NPY5RIGF1RPRMT5WDR77
SCHEMBL8054838 0.82 PIK3CA (0.36) PDE2AMAPK1KDM4EALDH1A1L3MBTL1
SCHEMBL8043906 0.80 PRMT5 (0.35) PDE2AMAPK1TDP1CASP1CASP7
SCHEMBL8043913 0.79 PIK3CA (0.36) MEN1KMT2AKDM4EALDH1A1IGF1R
SCHEMBL8041870 0.78 PIK3CA (0.34) KDM4EALDH1A1DYRK1AKCNH2IGF1R
SCHEMBL3228319 0.78 TGFBR2 (0.37) PDE2AMAPK1KDM4EALDH1A1RAB9A
SCHEMBL3231677 0.77 GSK3B (0.49)
SCHEMBL8046001 0.76 JAK2 (0.42) MAPK1DYRK1AKCNH2IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2010-10-07 US disclosed
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2010-10-07 US disclosed
WO-2009038385-A2 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHOONGWAE PHARMA CORPORATION (KR) 2009-03-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256133-A1 NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME MAP3K20, MAP3K3, MAP3K1 PDE2A 457/4885MAPK1 164/4885TDP1 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.